Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01742117 · ClinicalTrials.gov registry record · Phase 4
Tailored Antiplatelet Therapy Following PCI
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 5,276
- Enrollment target
NCT01742117: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT01742117 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 5,276 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01742117, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5,276 participants
- Enrollment target
Study Summary
Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some studies have suggested that patients who have a certain genetic liver enzyme abnormality (known as cytochrome P450 2C19 \[CYP2C19\] \*2 or \*3 allele) may have a reduced ability to activate clopidogrel, and therefore may have a lowered response to clopidogrel. It is thought that perhaps people who have a coronary stent procedure may have this genetic liver enzyme abnormality. There is a research genetic test available to determine whether or not someone has this genetic liver enzyme abnormality. Ticagrelor, is a newer anti-platelet drug that is not dependent on the CYP2C19 liver enzyme for its activation and hence in poor clopidogrel metabolizers, alternative drugs like Ticagrelor have been recommended for use as an anti-platelet agent after PCI. The purpose of this study is to determine if genetic testing can identify the best anti-platelet therapy, for patients who undergo a coronary stent placement and do not activate clopidogrel very well.
Interventions
- DRUG Clopidogrel
- DRUG Ticagrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,276 participants |
| Start Date | 2013-05 |
| Est. Completion | 2020-10-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01742117
The ClinicalTrials.gov registry entry for NCT01742117 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 5,276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clopidogrel is the first listed.
NCT01742117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01742117 about?
NCT01742117 is a clinical study titled "Tailored Antiplatelet Therapy Following PCI". Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some studies have suggested...
What is the current status of trial NCT01742117?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5,276 participants. The study started on 2013-05. Estimated completion is 2020-10-31.
What interventions are being tested in trial NCT01742117?
The interventions under investigation include: Clopidogrel (DRUG), Ticagrelor (DRUG).
Who is sponsoring clinical trial NCT01742117?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.